Considerable interest has been directed toward the role innate immunity plays in reducing malignant growth and progression. Although the innate system by broad definition is not endowed with the antigen specificity and memory recall of adaptive immunity, natural killer (NK) cells are an innate effector population that shares most properties with the adaptive arm of the immune system, excluding receptor rearrangement (28) . Interestingly, NK cells can be employed to directly target and destroy malignant cell types through diverse pathways that include tumor major histocompatibility complex class I (MHC-I) loss and upregulation of stressinducible protein ligands for the NK cell activating receptor NKG2D (24, 29) . Much effort is under way in human clinical trials to manipulate NK cell properties for directed therapies against cancer (13, 29) .
One strategy in eliciting innate immunity in general involves activating the Toll-like receptor (TLR) family, which are preferentially expressed by innate effectors such as NK cells, macrophages, and dendritic cells (DCs) (26) . TLR ligands include a variety of pathogen-associated molecular patterns with differing downstream responses based on the cell type involved and specific TLR activated. In TLR-expressing cells, signal transduction pathways follow a MyD88-independent course to produce type I interferons (IFNs) (e.g., TLR3) or a MyD88-dependent pathway that results in the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-␣), interleukin-1 (IL-1), and IL-6 and expression of costimulatory molecules such as CD40, CD80, and CD86 (e.g., TLR4 and TLR9) (2, 12, 23, 26) . In the case of TLR3, activation by poly(I:C) causes DCs and additional accessory cells to secrete type I interferons and IL-12, activating NK cells and prompting NK cell secretion of IFN-␥ among other effects (14, 20) . Ultimately, modulation of TLR activation results in the generation of a range of cytokines that promote inflammation, Th1 bias, and NK cell-directed killing that can be utilized in a beneficial manner for tumor treatment strategies.
TLR agonist incorporation alongside vaccine strategies has resulted in promising results in mouse models of cancer (12) . Indeed, the TLR7 agonist imiquimod is an effective FDAapproved topical compound used to treat superficial basal-cell carcinoma and external genital warts (9) . However, to our knowledge, modulating TLR activity while also incorporating recombinant simian virus 40 (SV40) large tumor antigen (Tag) protein immunizations in a therapeutic tumor setting has not been previously reported. SV40 Tag is a clinically relevant tumor-specific antigen that has been shown to be expressed by a number of human malignancies, including malignant pleural mesothelioma (MPM), and represents a potential target for immunotherapeutic strategies.
Our laboratory has previously defined a unique role for antibody-dependent cell-mediated cytotoxicity (ADCC) reactions-specific against SV40 Tag-promoting cytotoxic T-lym-phocyte (CTL) activity in response to neoantigens through cross-presentation of tumor cell debris in a model of experimental pulmonary metastasis (16, 17) . In this report, we analyze the role of innate immunity in mediating tumor cell lysis during the early course of tumorigenesis in the absence of vaccination. Overall, we find that activated NK cells are necessary effector cells in achieving antitumor reactions and providing partial tumor immunity during the onset of tumorigenesis and that these functioning NK cells are likely activated in vivo due to inflammation as a result of tumor growth and progression. The burden of tumor challenge could be further reduced in naive animals with the indirect activation of NK cells using poly(I:C) as a TLR3 agonist prior to and during malignant dissemination. Interestingly, in an established pulmonary tumor setting, therapeutic treatment of mice with poly(I:C) and recombinant SV40 Tag resulted in enhanced protection that was not observed using poly(I:C) or SV40 Tag alone. One effect of instituting poly(I:C) treatment alongside SV40 Tag immunizations was a Th1 skewing of the SV40 Tag IgG antibody response that correlated with therapeutic tumor protection.
Our results have direct implications for the prevention and treatment of malignancies, such as MPM, that express the SV40 Tag oncoprotein. Combining specific aspects of innate and adaptive immunity by targeting both NK cells and humoral activity against SV40 Tag, respectively, represents a novel and clinically significant immunotherapeutic strategy for potential use in patients.
MATERIALS AND METHODS
Cells and media. The SV40-transformed BALB/c kidney sarcoma cell, designated mKSA (15a), was used for in vivo tumor challenge and in vitro cell cytotoxicity studies. The A/Sn lymphoma cell line Yac-1 was incorporated as an NK-sensitive control in the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) in vitro assay. All cells were cultured in high-glucose Dulbecco's modified Eagle medium (DMEM) with L-glutamine (HyClone, Logan, UT) and supplemented with 0.1 mM nonessential amino acids (Sigma, St. Louis, MO), 100 U/ml penicillin (Sigma, St. Louis, MO), 500 g/ml streptomycin (Sigma), and 10% heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA). Cells were incubated at 37°C in a 5% CO 2 atmosphere. Before administration into mice, mKSA cells were washed, detached from flasks using 1 mM EDTA-phosphate-buffered saline (PBS) (pH 7.5), and adjusted to 1 ϫ 10 5 cells per 50 l in PBS.
Mice and tumor cell challenge. Six-to 8-week-old BALB/c mice were obtained from Charles River Laboratories (Wilmington, MA). The treatment and care of animals were in accordance with institutional guidelines and the Animal Welfare Assurance Act. Animals were inoculated intravenously (i.v.) with a lethal dose of 1 ϫ 10 5 mKSA cells. To assess tumor burden, lungs were obtained from euthanized mice 18 days after tumor challenge and analyzed for the presence of lung tumor foci. Lungs were stained with 10% India ink through intratracheal injection, excised, and destained in a formalin-based solution. Enumeration of tumor foci on the ventral surface of the lung was carried out using the FluorChem 8000 digital imaging system (Alpha Innotech Co., San Leandro, CA). To ensure consistency of counting and minimize subjectivity, visual parameters related to the density and diameter of lung foci were controlled between samples. We have described these methods in detail previously (32, 33) . In vivo depletion of NK cells. BALB/c NK cells were depleted in vivo using the rabbit polyclonal IgG antibody anti-mouse Asialo GM1 (Cedarlane Laboratories, Burlington, NC). The depletion reagent was first purified using a protein A column, and total IgG protein content was approximated by measuring absorbance at 280 nm. Purified anti-Asialo GM1 and a control rabbit IgG preparation were administered intraperitoneally (i.p.) a total of 4 times at 250 g in 0.1 ml PBS according to the depletion schemes detailed in Fig. 3 and 4C .
The efficacy of NK cell depletion in animals was determined through flow cytometry using the pan marker CD49b (clone DX5) (BD Biosciences, Franklin Lakes, NJ). More than 95% of NK cells were depleted compared to results for untreated and rabbit IgG-treated mice (data not shown).
TLR activation. TLR3 was activated in vivo with i.p. injections of 100 g of the specific agonist poly(I:C) (Sigma) in 0.1 ml PBS 2 days before and 2 days after mKSA tumor cell challenge according to the schedule outlined in Fig. 4A . Poly(I:C) (50 g) was also employed as a therapeutic strategy for tumor challenge by following the treatment scheme in Fig. 5A .
The direct lysis effects of poly(I:C) on mKSA tumor cells were assessed using a modified MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] in vitro assay. mKSA cells (4 ϫ 10 4 ) were grown overnight in DMEM without phenol red (Invitrogen, Carlsbad, CA) in 96-well plates. Medium in wells was replaced with 100 l fresh medium containing various concentrations (0.2 to 10.0 g/ml) of poly(I:C) and incubated at 37°C for 3 h. Wells were washed, medium was replaced with 100 l fresh medium containing 10 l 12 mM MTT, and wells were further incubated for 4 h. In order to lyse cells and solubilize the formazan product, 100 l of SDS (1%)-HCl (0.01 M) was added to wells and incubated overnight at 37°C. Plate absorbance was read at 560 nm, and optical density (OD) values obtained from medium alone with MTT were used for background corrections.
ELISA. SV40 Tag IgG antibody was detected in sera from immunized mice through indirect enzyme-linked immunosorbent assay (ELISA) as described by our laboratory (17, 19) . Briefly, 200 ng of recombinant SV40 Tag in boratebuffered saline (BBS) was used to coat 96-well microtiter plates overnight at 4°C. Wells were blocked with the addition of 200 l BBS-FBS (2%)-Tween 20 (0.05%) and incubated for 30 min at 37°C. Serum samples were added in triplicate at a 1:50 dilution in blocking buffer and incubated at 37°C for 1 h. Wells were washed using BBS-Tween 20 (0.05%) and probed with a horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (␥ chain) reagent (KPL, Inc., Gaithersburg, MD) at a 1:5,000 dilution in blocking medium for 30 min at 37°C. Wells were washed and developed with 100 l ABTS [2,2Ј-azinobis(3-ethylbenzthiazolinesulfonic acid)] containing 0.01% H 2 O 2 . An OD reading at 410 nm that was determined to be approximately three times the OD values obtained for a 1:50 dilution of preimmune sera was established as a cutoff for positive reactivity.
The predominant SV40 Tag-specific IgG isotype was also determined in serum samples with slight modification to the above protocol. After the binding of sera to SV40 Tag at a 1:400 dilution, plates were washed in BBS-Tween 20 and incubated for 1 h at 37°C with 50 l rabbit anti-mouse IgG1 or IgG2a (Bio-Rad, Hercules, CA). Wells were then washed and probed with a 1:500 dilution of goat anti-rabbit IgG HRP-labeled reagent (KPL, Inc.) for 30 min at 37°C. After wells were washed, plates were developed with ABTS as explained above. The SV40 Tag-specific monoclonal antibodies PAb 405 (IgG1) and PAb 419 (IgG2a) were used as positive controls and as a check for any cross-reactivities between the rabbit anti-mouse IgG reagents. IgG2a/IgG1 ratios were determined from the mean OD values at 410 nm as previously described by our group (15) .
NK cell isolation and activation. Spleens from naive BALB/c mice were harvested and homogenized, and the bulk cell suspension was layered over Histopaque-1077 (Sigma). Monocytes were then isolated through sucrose gradient centrifugation by following the manufacturer's instructions. Any remaining red blood cells in the cell suspension were ruptured using ACK lysing buffer (Sigma).
NK cells were enriched through negative magnetic bead selection. Briefly, biotin-labeled antibodies against CD4 (L3T4) (clone RM4-5), CD8a (Ly-2) (clone 53-6.7), CD19 (clone 1D3), and Ly6-G/Ly6-C (clone RB6-8C5) (BD Biosciences) were incubated with 1 ϫ 10 7 mononuclear cells for 20 min at 4°C. Biotin-labeled cells were then removed using MyOne streptavidin T1 beads (Invitrogen) by following the manufacturer's instructions. Purity of the enriched activated NK cell fraction was assessed by flow cytometry against CD16, CD25, and CD49b (clone DX5) (BD Biosciences) and was greater than 95%. To activate the enriched NK cell suspension in culture, IL-2 (500 U/ml) (eBioscience, San Diego, CA) was added to DMEM and cells were cultured for 4 days at 37°C.
GAPDH-coupled luminescence assay. In vitro cell lysis of mKSA cells was analyzed by correlating GAPDH release with a coupled luminescence technology using the aCella-Tox kit (Cell Technology, Mountain View, CA). mKSA cells were plated in triplicate at 5 ϫ 10 3 cells in 96-well culture plates and incubated overnight at 37°C with 5% CO 2 . Wells were resuspended in a total volume of 50 l DMEM, and naive or activated NK cells were added at various effector-totarget (E:T) ratios (based on a target of 1 ϫ 10 4 mKSA cells) in 50 l medium. The plate was centrifuged at 250 ϫ g for 2 min and incubated for 4 h at 37°C with 5% CO 2 . Spontaneous GAPDH release was determined in control wells that included only mKSA or NK cells. After the intended incubation period, total GAPDH release was determined in mKSA cells alone with the addition of 1 l of the lytic reagent (NP-40) and a 10-min incubation at room temperature. Plates were centrifuged for 3 min at 500 ϫ g, and cell-free supernatants were transferred to a white 96-well assay plate (Corning Inc., Corning, NY).
One hundred microliters of 2ϫ enzyme assay reagent containing glyceraldehyde-3-phosphate was added to all wells. Fifty microliters of detection reagent containing luciferase/luciferin was immediately added, and the plate was read using the Modulus microplate multimode reader (Turner BioSystems, Sunnyvale, CA). Wells containing only medium served as background, and background values were subtracted from values for samples prior to the determination of specific GAPDH release. Percent cytotoxicity was calculated as follows: {1 Ϫ [(GAPDH-specific release Ϫ target spontaneous release Ϫ effector spontaneous release)/(GAPDH maximum target release Ϫ target spontaneous release)]} ϫ 100. Spontaneous release of either mKSA or NK cells was below 10% of the maximum mKSA release.
Flow cytometry and antibody cytokine array. To determine the extent of inflammation following tumor challenge, groups of mice were inoculated with 1 ϫ 10 5 mKSA cells and splenocytes were harvested 0 and 14 days after tumor challenge by sucrose gradient centrifugation. The final pellet, consisting of 1 ϫ 10 6 cells, was resuspended in 5 ml RPMI medium with phorbol myristate acetate (PMA; 50 ng/ml)-ionomycin (1 M)-brefeldin A (1 g/ml) for intracellular flow cytometry or PMA-ionomycin for antibody cytokine arrays and stimulated for 5 h at 37°C. We have described our flow cytometry methods in detail previously (17) . Briefly, after wash and block steps, surface CD3 ϩ cells were targeted using phycoerythrin (PE)-Cy5-conjugated anti-mouse CD3e (145-2C11) (BD Biosciences). Cells were fixed and permeabilized by resuspension in 100 l BD Perm/Wash that contained 100 ng of PE-conjugated anti-mouse TNF-␣, IFN-␥ (XMG1.2), or IL-2. Pelleted cells were then reconstituted in 1 ml fluorescenceactivated cell sorter (FACS) flow sheath fluid and analyzed with a Becton Dickinson FACSVantage SE instrument using CellQuest software. Sample analysis involved gating first on CD3 ϩ cells, followed by the examination of intracellular expression of TNF-␣, IFN-␥, or IL-2. Data are presented as the total percentage of CD3 ϩ cells for the specific cytokine under investigation from the average of 3 individual mice per group.
In splenocytes stimulated without brefeldin A, cell-free supernatants from each individual mouse were obtained by centrifugation. Seven hundred microliters from each sample per group was pooled and analyzed for the expression of a panel of cytokines using the mouse antibody array kit (Panomics, Fremont, CA) by following the manufacturer's instructions. After developing membranes, chemiluminescence reactions were captured using a Typhoon imaging system (GE Healthcare, Piscataway, NJ), and scanned images were analyzed using the software program ImageQuant (GE Healthcare).
Statistical analysis. Unless otherwise noted, data comparisons between two independent groups involved unpaired two-sample t-test analysis, with significance indicated at P values Ͻ0.05. In the case of animal experiments containing more than two treatment groups, lung tumor focus values were logarithmically transformed and assessed by one-way analysis of variance (ANOVA) followed by Tukey's honestly significant difference (HSD) test, with significance detailed at P values Ͻ0.05.
RESULTS
Inflammation results from mKSA tumor cell challenge. To assess the state of inflammation in vivo, naive mice were challenged with mKSA cells and splenocytes were harvested 0 and 14 days following tumor inoculation. Cells were stimulated in vitro for 5 h in PMA-ionomycin with or without brefeldin A depending on the downstream application of flow cytometry or antibody array, respectively.
In the case of intracellular expression of inflammatory cytokines, CD3 ϩ splenocytes were analyzed by FACS for levels of TNF-␣, IFN-␥, and IL-2. As shown in Fig. 1A , percentages of TNF-␣ and IL-2 were significantly greater in 14 day splenocytes than in cells obtained from animals challenged at day 0 (P Ͻ 0.05; two-sample t test). More specifically, mean TNF-␣ levels were 1.75% of CD3 ϩ splenocytes at day 0 and 9.51% of CD3 ϩ cells at 14 days after mKSA tumor cell challenge. The average IL-2 levels were 1.68% and 2.71% of CD3 ϩ splenocytes at days 0 and 14, respectively, following tumor cell inoculation.
Pooled supernatants from in vitro-stimulated splenocytes were also assessed for a panel of inflammatory cytokines using antibody array blots. A number of cytokines were detected in the culture medium, including IFN-␥ and MIP-1␣. However, densitometer analysis of developed blots indicated an approximately 1.5-fold increase in levels of IL-4 and an approximately 1.4-fold increase in RANTES at 14 days compared to cytokine levels at 0 days postchallenge (P Ͻ 0.05; two-sample t test) (Fig. 1B, panel II) .
Altogether, when assessing splenocyte expression of inflammatory cytokines, these data support the hypothesis that tumor challenge induces a heightened inflammatory response at least 2 weeks after i.v. injection of mKSA cells.
IL-2-stimulated NK cells mediate tumor cell killing in vitro. Since expression levels of inflammatory cytokines were greater in naive mice following tumor inoculation, we next wanted to assess whether an innate immunologic component, such as NK cells, was involved in eliciting tumor cell lysis prior to the induction of adaptive immunity within our experimental pulmonary metastasis model.
To determine the killing effects of NK cells, we analyzed the direct lysis of mKSA cells in vitro using a chemiluminescence GAPDH release assay. Resting NK cells were first enriched from splenocytes of naive BALB/c mice using negative magnetic bead separation. NK cells were either left unstimulated or transferred to culture in DMEM with IL-2 (500 U/ml) and incubated for 4 days at 37°C with 5% CO 2 . mKSA cells were plated overnight in DMEM at 5 ϫ 10 3 cells/well prior to further treatment. Either unstimulated or IL-2-enhanced NK cells were added to wells with mKSA at various E:T ratios based upon 1 ϫ 10 4 mKSA cells and incubated for 4 h at 37°C. Cell-free supernatants were then obtained and analyzed for the presence of GAPDH as described in Materials and Methods.
In our initial tests, resting NK cells failed to lyse mKSA cells (Fig. 2) . These unstimulated NK cells were functionally active based upon over 40% lysis of Yac-1 cells. However, when NK cells were stimulated in culture with IL-2 for several days, approximately 20% of mKSA cells were readily lysed at a 15:1 E:T ratio. In replicate experiments using pristane-primed peritoneal macrophages, mKSA cytotoxicity was not observed (data not shown). Although we did not directly study the NK ligand(s) involved in mKSA lysis, MHC-I expression patterns on mKSA cells do not appear to be involved. More than 95% of mKSA cells readily stained for H-2K d and H-2D d by flow cytometry (data not shown).
NK cell depletion in vivo abrogates mKSA tumor cell protection. We extended our in vitro observations of NK cellmediated mKSA tumor cell killing to BALB/c mice experimentally challenged with a lethal dose of mKSA cells. Our tumor challenge model was set up to determine the protective effects of NK cells during the innate immune response to mKSA tumor cells. On days Ϫ3, Ϫ1, 1, and 3, groups of mice received i.p. injections of either a rabbit IgG control preparation or anti-mouse Asialo GM1 (anti-NK). Mice received 1 ϫ 10 5 mKSA cells i.v. on day 0. Eighteen days following tumor challenge, animals were euthanized and lungs were stained and excised for the presence of lung tumor foci.
As detailed in Fig. 3 , animals receiving rabbit IgG developed on average 6.8 foci (range of 4 to 10 foci). This was expected given that unprotected animals succumb to tumor challenge Prophylactic TLR stimulation in vivo dramatically reduces lung tumor burden. Since innate immunity, and NK cells in particular, appeared to play a role in reducing tumor load in our experimental pulmonary metastasis model, we assessed whether further activation of the innate system-and, more specifically, NK cells-through TLR ligation would impact antitumor responses. Mice were administered i.p. injections of the TLR3 agonist poly(I:C) (100 g) on days Ϫ2 and 2, while tumor challenge of mKSA tumor cells was carried out on day 0 (Fig. 4A) . Eighteen days following tumor inoculation, mice were euthanized and lungs were assessed for the extent of tumorigenic growth.
Animals receiving 2 injections of poly(I:C) prior to and after tumor challenge had an overwhelmingly reduced lung tumor load compared to control mice receiving injections of PBS. As shown in Fig. 4B , poly(I:C) injections resulted in partial to complete protection from mKSA inoculation. In separate experiments, in vivo activation of NK cells through TLR9 ligation with i.p. injections of 30 g oligodeoxynucleotides (ODNs) resulted in a similar pattern of tumor protection (data not shown).
To assess the in vivo role of poly(I:C) in NK cells, animals receiving two injections of poly(I:C) were administered either anti-Asialo GM1 or rabbit IgG on days Ϫ4, Ϫ3, Ϫ1, and 1 relative to mKSA tumor cell challenge on day 0. As shown in Fig. 4C , mice treated with poly(I:C)-rabbit IgG were partially protected from mKSA tumor development and contained an average of 1.3 lung foci (range of 1 to 2 foci). Tumor burden was statistically increased in animals depleted of NK cells while also receiving poly(I:C) injections (mean lung tumor foci, 7.5; range of 3 to 10 foci) (P Ͻ 0.05; ANOVA), indicating that poly(I:C) was instrumental in initiating NK cell lysis of mKSA tumor cells. However, the protective effects of poly(I:C) in vivo were multifaceted since lung tumor focus values for mice treated with poly(I:C) and anti-NK were significantly reduced compared to those for animals depleted of only NK cells (mean lung tumor foci, 19; range of 16 to 22 foci) (P Ͻ 0.05; ANOVA).
The direct killing effects of poly(I:C) (up to 10 g/ml) on mKSA tumor cells in vitro were also found to be negligible when assessed by MTT assays (Fig. 5) , again supporting the notion that poly(I:C) was most likely functioning in vivo to elicit indirect activation of innate effector cells such as NK cells (14, 20) .
These results are striking considering that poly(I:C)-treated mice were not previously vaccinated against SV40 Tag and, thus, had no prior sensitization to tumor cells. Previous work from our laboratory has indicated a required initial role for SV40 Tag-specific antibody in achieving complete protection from mKSA tumor development when recombinant protein or plasmid DNA is utilized as a prophylactic vaccine (4, 19, 31) .
Eliciting innate and humoral immunity in a therapeutic setting results in increased protection from the development of lung tumor foci. We next wanted to assess the efficacy of inducing innate immunity through poly(I:C) and humoral ac- . injections of either anti-Asialo GM1 or rabbit IgG on days Ϫ4, Ϫ3, Ϫ1, and 1. Tumor burden in lungs was then assessed tivity using recombinant SV40 Tag protein in a therapeutic challenge system. As diagramed in Fig. 6A , mKSA tumor cells were i.v. injected into mice on day 0 and allowed to establish for 2 days prior to any form of treatment. Poly(I:C) (50 g) was then delivered i.p. on days 2, 6, 11, and 16, with recombinant SV40 Tag protein i.p. injections on days 3, 8, and 13. Eighteen days following tumor challenge, sera were harvested from animals and analyzed by ELISA for the presence of SV40 Tagspecific IgG as well as for the predominant SV40 Tag-specific IgG2a or IgG1 isotype. Subsequent to obtaining sera, lungs from euthanized mice were stained and examined for the presence of tumorigenic growth.
Although in previous studies, prophylactic immunization with recombinant SV40 Tag protein resulted in complete protection within our experimental pulmonary metastasis model (15, 17, 31) , therapeutic delivery of SV40 Tag protein in alum had no observable effect on reducing tumor burden (mean lung tumor foci, 13.5) (Fig. 6B) . In animals given i.p. injections of poly(I:C) and alum, no significant differences in lung tumor focus values were achieved compared to the control SV40 Tag group (mean lung tumor foci, 10) (P Ͼ 0.05; ANOVA). These results are interesting given that poly(I:C) alone had a positive effect on achieving levels affording nearly complete protection when administered 2 days prior to and after i.v. challenge of mKSA tumor cells (Fig. 4B) . However, lung tumor burden could be reduced in animals receiving i.p. injections of both poly(I:C) and recombinant SV40 Tag protein in a therapeutic setting (mean lung tumor foci, 4) (P Ͻ 0.05; ANOVA). More specifically, combining these specific agonists for humoral and innate immunity resulted in lung tumor focus values that were 70% and 60% decreased compared to those for the SV40 Tag control and poly(I:C)-alum-treated groups, respectively. Sera were also analyzed in mice 18 days following mKSA tumor cell challenge for reactivity to SV40 Tag by ELISA. All mice in groups receiving therapeutic injections of recombinant SV40 Tag protein developed an SV40 Tag humoral response, whereas anti-SV40 Tag IgG was not observed in mice receiving injections of poly(I:C) and alum ( Table 1) . The SV40 Tag antibody responses appeared to be similar since titers to SV40 Tag in ELISAs were indistinguishable (data not shown). Yet, the predominant IgG isotypes in the SV40 Tag control and poly(I:C)-SV40 Tag-treated groups were different. Based on the ratios of IgG2a to IgG1 when using a commercial isotyping kit, a skewing of the antibody response toward Th1 from a Th2 response was evident in the poly(I: C)-SV40 Tag group (Table 1) .
Altogether, combining poly(I:C) and recombinant SV40 Tag protein injections in the therapeutic regimen resulted in superior protection from tumor cell challenge, which could not be achieved with either SV40 Tag or poly(I:C) alone. Since poly(I:C) shifted the nature of the antibody isotype among other effects, these data support the hypothesis that the efficacy of eliciting broad-based immunity involves inducing a Th1-directed SV40 Tag humoral response to achieve therapeutic tumor protection. ϩ T cells, which become cross-primed and mediate CTL reactions against SV40 Tag and neoantigens (17) .
In this report, we have furthered our knowledge of the immune-mediated pathways leading to tumor cell lysis, particularly as it relates to the innate phase against SV40 Tag. At least 2 weeks following i.v. challenge of mKSA tumor cells in naive mice, splenocyte expression of inflammatory cytokines was upregulated (Fig. 1) . It has been well characterized that inflammation typically results from tumorigenic growth (18, 25) . The prevailing thought with respect to inflammation is that inflammatory mediators initiate advanced malignant disease by disrupting effective antitumor responses through the induction of antagonistic pathways involving cell types such as CD4 ϩ regulatory T cells (Treg) and myeloid-derived suppressor cells, as well as promotion of angiogenesis (11) . However, within our own experimental pulmonary metastasis system, a Eighteen days following mKSA tumor challenge and therapeutic treatment with poly(I:C) and SV40 Tag, sera were analyzed for reactivity against SV40 Tag by indirect ELISA. Plus and minus signs indicate detectable or undetectable IgG antibody levels, respectively, at a 1:50 dilution of sera. The predominant IgG1 or IgG2a SV40 Tag-specific IgG isotype was also assessed in serum samples at a dilution of 1:400 by determining the ratio of IgG2a to IgG1 as detailed in Materials and Methods.
heightened levels of TNF-␣, IL-2, and RANTES in mKSA tumor cell-challenged mice appeared to correlate with beneficial immune-mediated reactions (Fig. 1, 2, and 3) . We hypothesize that these inflammatory mediators induce NK cell activation and migration among other antitumor effects as explained below (1, 27) . IL-4 upregulation after tumor challenge may serve to impair immune-mediated reactions in vivo since the cytokine is classically associated with downregulating Th1-based immune reactions while skewing the immune response toward a Th2 response (25) . Baschuk and colleagues have previously detailed the direct effects of IL-4 on SV40 Tag-mediated immune reactions (3) . In support of the results described here, the authors reported heightened levels of Tcell secretion of IL-4 up to 14 days after mKSA tumor cell challenge in SV40 Tag-immunized mice. Induction of IL-4 appeared to have a negative effect in vivo since IL-4 Ϫ/Ϫ mice developed an enhanced SV40 Tag-specific CTL response relative to wild-type mice. We have also demonstrated in a prophylactic setting that recombinant SV40 Tag immunization induces a predominant Th2 type response and that tumor immunity involves antibodies and not CTL responses specific for SV40 Tag (15) .
We next observed that activated NK cells play an important role in initiating mKSA tumor lysis in both in vitro and in vivo studies. IL-2-stimulated NK cells were capable of prompting mKSA tumor cell destruction in cell-based assays (Fig. 2) , while the disruption of NK cell function in vivo through antibody depletion resulted in increased lung tumor burden (Fig.  3) . The activation status of NK cells in our model was most important with regard to antitumor responses since naive NK cells did not lyse mKSA tumor cells in vitro (Fig. 2) . Although we were unable to elicit NK cell activation in culture with mKSA tumor cells over extended periods of time (our unpublished observations), prophylactic TLR3 sensitization through administration of poly(I:C) in naive mice was efficacious for NK cell function in vivo and resulted in increased tumor protection (Fig. 4 ). Our observations with NK-mediated lysis of mKSA tumor cells confirm and extend results of a previous study reporting the sensitivities of SV40-transformed cell lines to NK cells (10) . Although SV40 Tag was not directly responsible for tumor cell lysis by NK cells, it appeared that the oncoprotein played an indirect role since NK-mediated lysis was abrogated in cells expressing a truncated form of SV40 Tag. With our own results, SV40 Tag may serve as the primary target for activated NK cells in vivo, but this does not rule out other NK ligands expressed by mKSA tumor cells. The sensitivity of mKSA cells to NK cells does not appear to be MHC-I mediated based upon normal tumor expression of H-2K d and H-2D d (our unpublished observations). We are currently investigating the interactions between mKSA and NK cells more closely.
With respect to the innate phase of the immune response, we hypothesize that mKSA tumor cell challenge promotes inflammation through as yet unknown mechanisms. The initiation of innate immunity could be due to tissue damage that results from tumor spread and the lodging of mKSA cells in capillary beds, resulting in, for example, the elevation of inflammatory mediators such as TNF-␣, IL-2, and RANTES. What follows is activation of NK cells (presumably due to these inflammatory mediators), which are then able to destroy malignant cells without the aid of preexisting antibody to SV40 Tag. This described pathway of NK cell-driven lysis of mKSA tumor cells can be more efficiently modulated through prophylactic sensitization of TLR3.
We extended our observations concerning the innate phase response to mKSA tumor cell challenge and developed a therapeutic treatment regimen, combining aspects of innate and adaptive immunity, during the course of established experimental pulmonary metastasis. To our knowledge, this is the first report describing the antitumor effects of broad-based immunity by combining a TLR agonist with recombinant SV40 Tag protein immunization therapeutically within our experimental tumor challenge model. Although animals receiving only recombinant SV40 Tag protein or poly(I:C) alone did not appear to generate effective antitumor responses in vivo, tumor burden was reduced by well over 50% in mice administered both SV40 Tag and poly(I:C) (Fig. 6) . When sera from SV40 Tag-immunized mice were analyzed, it was found that poly(I:C) treatment shifted the SV40 Tag isotype response from IgG1 to IgG2a (Table 1) , as similarly reported for other animal model systems (14, 20) . IgG2a antibody molecules bind with higher affinity to Fc␥RIII (CD16), which is expressed by NK cells (21, 22) . Therefore, we hypothesize that the generation of a predominant SV40 Tag IgG2a antibody isotype would be more adept at engaging in ADCC reactions with activated NK cells in vivo and impacting treatment of established tumor growth. Indeed, we have previously described a vital role for ADCC in our experimental pulmonary metastasis model in vivo (16, 17) and have shown an increased propensity for SV40 Tag IgG2a monoclonal antibody molecules to initiate ADCC-mediated mKSA tumor cell lysis over SV40 Tag IgG1 in vitro (6) .
The overall results from this study highlight the power of eliciting innate immunity to increase the efficacy of immunebased reactions against SV40 Tag. Human malignancies such as MPM have been reported to express the SV40 Tag viral oncoprotein, while MPM patients have been observed to harbor CTL reactivity against SV40 Tag epitopes (5, 7, 8, 30) . Our results lend support to the potential clinical use of immunotherapeutic strategies that combine broad-based aspects of innate (e.g., TLR agonists) and humoral immunity for the preventative and therapeutic treatment of modalities that target tumors that express virally encoded or tumor-specific antigens.
